Learn More 53.9% Without Speciality Urologists who reported they were general urologists without a primary subspecialty Learn More
Using MDS-UPDRS part III scores in the ON-condition at month 12 as primary outcome the trial found a statistically significant difference in favour of lixisenatide of 3 score points, but there was no significant difference on any of the secondary efficacy outcomes including MDS-UPDRS part II scores
Its usually administered via subcutaneous injection and is available only by prescription
In placebo-controlled trials, severe GI reactions were reported in 1.7% (5 mg), 2.5% (10 mg), and 3.1% (15 mg) of Zepbound-treated patients compared to 1% of placebo-treated patients
However, several cost-reduction options exist
Additionally, GLP-1 RAs might stimulate sirtuin proteins like SIRT1, which play a crucial role in maintaining telomere integrity and preventing cellular senescence